Abstract
There is an ongoing need of developing sensitive and specific methods for the determination of SARS-CoV-2 seroconversion. For this purpose, we have developed a multiplexed flow cytometric bead array (C19BA) that allows the identification of IgG and IgM antibodies against three immunogenic proteins simultaneously: the spike receptor-binding domain (RBD), the spike protein subunit 1 (S1) and the nucleoprotein (N). Using different cohorts of samples collected before and after the pandemic, we show that this assay is more sensitive than ELISAs performed in our laboratory. The combination of three viral antigens allows for the interrogation of full seroconversion. Importantly, we have detected N-reactive antibodies in COVID-19-negative individuals. Here we present an immunoassay that can be easily implemented and has superior potential to detect low antibody titers compared to current gold standard serology methods.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We thank Petros Tyrakis and Ivan Martinez-Forero for critical reading and editing of the manuscript. Grant support: Support was provided by the Severo Ochoa Excellence Accreditation from MCIU (SEV-2016-0644) and the SPRI I+D COVID-19 fund (Gobierno Vasco). Personal fellowships: A.A.V. (La Caixa Inphinit), A.B. (AECC Bizkaia), A.G.D.R (Bikaintek), A.P. (Ramon y Cajal), B.J.L. (Gob. Vasco) and E.P.F. (Juan de la Cierva-Formacion). M.L.M.C. acknowledges RTC2019-007125-1, DTS20/00138, SAF2017-87301-R, and BBVA UMBRELLA project. M.L.H. acknowledges the ISCIII for grant COV20-0170 and the Government of Cantabria for grant 2020UIC22-PUB-0019. O.M.-J.M.M. and N.G.A.A. acknowledge the Agencia Estatal de Investigacion (Spain) for grants CTQ2015-68756-R, RTI2018-101269-B-I00 and RTI2018-095700-B-I00, respectively. A.P. has received grant funding from the European Research Council (ERC), grant agreement number 804236 (Horizon 2020), and the FERO Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Serum samples corresponding to preCOVID and acute COVID individuals were provided by the Basque Biobank (www.biobancovasco.org) after approval from the corresponding ethics committee (CEIC-E 20-26, 1-2016). All participants in the study provided informed consent and were anonymized. The serum samples corresponding to the acute COVID cohort (43 patients presenting COVID-19 symptomatology and diagnosed by PCR) were obtained at time of hospital admission. The preCOVID cohort (50 serum samples) was obtained during the yearly medical check-up of the working population of the Basque Country in 2018-2019 in collaboration with Osarten Kooperatiba Elkartea from Mondragon Corporation. Additional serum samples from negative controls (n=18) and independent COVID-19 cohorts confirmed by PCR were obtained after written informed consent and approval by the Cantabria Ethics Committee (CEIm Code: 2020.167). Serum samples from 34 patients with active infection were obtained at time of hospital admission, and samples from 20 convalescent patients were obtained one month after recovery from COVID-19. Severity of the disease was defined as mild/moderate (n=18) or severe (n=16). Severity was classified based on admission to the intensive care unit (ICU), and oxygen levels as defined previously.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Version of the manuscript after consideration of the reviewers' comments (Round 1).
Data Availability
All the data of this work are included within the manuscript.
